Genelux (GNLX) Convertible Debt (2022 - 2023)

Genelux (GNLX) posted quarterly Convertible Debt of $40000.0 for Q3 2023, down 38.46% quarter-over-quarter from $65000.0 in Q2 2023.

Genelux (GNLX) Convertible Debt (2022 - 2023) Analysis & Trends

Genelux's Convertible Debt history runs 2 years deep, the most recent figure standing at $40000.0 for Q3 2023.

In Q3 2023, Convertible Debt changed N/A year-over-year to $40000.0; the TTM figure through Sep 2023 stood at $40000.0 (changed N/A YoY), while the FY2022 annual figure was $15.4 million, changed N/A from the prior year.
Convertible Debt for Q3 2023 stood at $40000.0, down from $65000.0 in the prior quarter.
The five-year high for Convertible Debt was $15.4 million in Q4 2022, with the low at $40000.0 in Q3 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn
10	Genelux	120.53 Mn	120.53 Mn	-

Download Data